Challenges in implementing government-directed VTE guidance for medical patients: a mixed methods study by Basey, AJ et al.
Challenges in implementing
government-directed VTE guidance for
medical patients: a mixed methods study
Avril Janette Basey,1,2 Janet Krska,3 Tom D Kennedy,4 Adam John Mackridge2
To cite: Basey AJ, Krska J,
Kennedy TD, et al. Challenges
in implementing government-
directed VTE guidance for
medical patients: a mixed
methods study. BMJ Open
0;2:e001668. doi:10.1136/
bmjopen-2012-001668
▸ Prepublication history and
additional material for this
paper are available online. To
view these files please visit
the journal online
(http://dx.doi.org/10.1136/
bmjopen-2012-001668).
Received 14 June 2012
Accepted 3 October 2012
This final article is available
for use under the terms of
the Creative Commons
Attribution Non-Commercial
2.0 Licence; see
http://bmjopen.bmj.com
1Pharmacy Department,
Royal Liverpool University
Hospital, Liverpool, UK
2School of Pharmacy and
Biomolecular Sciences,
Liverpool John Moores
University, Liverpool, UK
3Medway School of
Pharmacy, The Universities of
Greenwich and Kent at
Medway, Chatham, Kent, UK
4Acute Medical Unit, Royal
Liverpool University Hospital,
Liverpool, UK
Correspondence to
Avril Janette Basey;
A.Basey@2009.ljmu.ac.uk
ABSTRACT
Background: Implementing venous thromboembolism
(VTE) risk assessment guidance on admission to
hospital has proved difficult worldwide. In 2010, VTE
risk assessment in English hospitals was linked to
financial sanctions. This study investigated possible
barriers and facilitators for VTE risk assessment in
medical patients and evaluated the impact of local and
national initiatives.
Setting: Acute Medical Unit in one English National
Health Service university teaching hospital.
Methods: This was a mixed methods study; National
Research Ethics Service approval was granted. Data
were collected over four 1-week periods; November
2009 (1), January 2010 (2), April 2010 (3) and April
2011 (4). Case notes for all medical patients admitted
during these periods were reviewed. Thirty-six staff
were observed admitting 71 of these patients; 24
observed staff participated in a structured interview.
Results: 876 case notes were reviewed. In total,
82.1% of patients had one or more VTE risk factors
and 25.3% one or more bleeding risks. VTE risk
assessment rose from a baseline of 6.9–19.6%,
following local initiatives, and to 98.7% following
financially sanctioned government targets. A similar
increase in appropriate prescribing of prophylaxis was
seen, but inappropriate prescribing also rose. No staff
observed in period 1 conducted VTE risk assessment,
risk-assessment forms were largely ignored or
discarded during period 2; and electronic recording
systems available during period 3 were not accessed.
Few patients were asked any VTE-related questions in
periods 1, 2 or 3.
Interviewees’ actual knowledge of VTE risk was not
related to perceived knowledge level. Eight of the 24
staff interviewed were aware of national policies or
guidance: none had seen them. Principal barriers
identified to risk assessment were: involvement of
multiple staff in individual admissions; interruptions;
lack of policy awareness; time pressure and complexity
of tools.
Conclusions: National financial sanctions appear
effective in implementing guidance, where other local
measures have failed.
ARTICLE SUMMARY
Article focus
▪ Implementing venous thromboembolism (VTE)
risk assessment (RA) on admission to hospital
is proving difficult.
▪ What are the barriers and facilitators for carrying
out VTE RA when admitting medical patients?
▪ What was the impact of national and local initia-
tives designed to maximise VTE RA and appro-
priate prophylaxis with low-molecular-weight
heparin (LMWH)?
Key messages
▪ A variety of locally designed initiatives proved
ineffective in improving performance in carrying
out VTE RA whereas a centrally imposed finan-
cial sanction appeared effective.
▪ Increased frequency of VTE RA resulted in an
increase in both appropriate and inappropriate
prescribing of LMWH.
▪ Staff knowledge of VTE risk factors and policy
was poor possibly contributing to poor
performance.
Strengths and limitations of this study
▪ The observations and interviews provide rich
real-time data supporting and informing the find-
ings of the case note review.
▪ The numbers of case notes reviewed were suffi-
ciently large to provide statistically significant
comparisons between study periods.
▪ The study was carried out in one hospital; the
practices observed and opinions expressed may
not reflect those in other hospitals.
▪ The researcher is a regular member of the AMU
staff which may have impacted on behaviour
during observations.
▪ The interviews were carried out sequentially and
although all staff agreed to keep the subject
matter confidential to avoid invalidating the
results, it is impossible to be certain that confi-
dentiality was not breached, but no evidence
suggests that this occurred.
▪ Staffs interviewed were not asked about any recent
changes to their practice regarding VTE RA.
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INTRODUCTION
Venous thromboembolism (VTE) was ﬁrst described in
1676 and its association with surgery recognised in 1866.1
During the 20th century, accumulating evidence of risk
factors for VTE, especially those associated with surgery,
led to the ﬁrst consensus statement for preventing VTE
and pulmonary embolism (PE) in 1986.2 The link between
inﬂammation and increased VTE risk was ﬁrst proposed in
the 1970s3 and the increased risk of VTE associated with
medical conditions which have an inﬂammatory compo-
nent, such as respiratory disease and acute infection, is
now recognised.4 Not surprisingly, the proportion of
patients developing VTE increases with the number of risk
factors present,5 but over 80% of medical patients admitted
to hospital have at least one risk factor.6 7 The risk of deep
vein thrombosis (DVT) in hospitalised medical patients if
no thromboprophylaxis is given was approximately 20% in
a meta-analysis of 17 randomised clinical trials.8
Prophylaxis with low-molecular-weight heparin (LMWH)
reduces the number of hospital-acquired VTEs in medical
patients by up to 60%.9 10
Increased international awareness of VTE risks is shown
by studies assessing current practice in Europe,11 12 Brazil,13
the USA14 15 and Canada.16 In England and Wales this
awareness has been seen at government level, through the
commissioning of reports in 200417 and 2007,18 the National
Institute For Health and Clinical Excellence (NICE) pub-
lished guidance on risk assessment (RA) in 201019 and most
recently mandatory collection of VTE RA ﬁgures as part of
the National Health Service (NHS) Outcomes Framework
in June 2010.20 This top down approach has had limited
success, with uptake of VTE RA guidance slow and many
NHS hospitals struggling with its implementation.6 21–23 The
report based on the Commissioning for Quality and
Innovation payment framework (CQUIN) data collection
for July–September 2011 shows that 12 months after manda-
tory implementation some English NHS hospitals were still
unable to fully comply with the target that 90% of patients
should be assessed within 24 h of admission. Overall only
88% of all patients (medical and surgical) were VTE risk
assessed on admission and in September 2011, 18% of hos-
pitals failed to meet the 90% target.24 This problem is not
unique to England and Wales. The ENDORSE study, which
was conducted in 32 countries worldwide in 2008, showed
that recommended VTE prophylaxis in medical patients
varied between countries from 3% to 70%.25
Given the difﬁculties in implementing guidance, this
study aimed to (1) identify possible barriers and facilita-
tors for carrying out VTE RA and appropriate prophylac-
tic prescribing in medical patients and (2) assess the
impact of these national initiatives and other local initia-
tives on VTE RA on admission and prophylaxis in one
English NHS university teaching hospital.
METHODS
A triangulated mixed methods approach was used involv-
ing review of case notes, observation of the admission
process and interviews with healthcare staff. There were
four 1-week study periods: November 2009 (1), January
2010 (2), April 2010 (3) and April 2011 (4). Case note
review and direct observation of a sample of admissions
was carried out for all four study periods. Interviews
were undertaken with all admitting staff observed during
periods 1, 2 and 3. The data collection periods were
selected to assess the impact of both local and national
initiatives occurring during the study and also to avoid
the weeks when junior doctors change jobs to minimise
bias due to lack of familiarity with the role (ﬁgure 1).
1. November 2009—All Party Parliamentary
Thrombosis Group—Audit of acute trusts (National)
2. 24 November 2009—Trust RA forms placed with
medication charts on AMU (Local)
3. 27 January 2010—NICE guidance—national press &
TV coverage (National)
4. 15 February 2010—Thrombosis nurse employed
(Local)
5. 26 February 2010—VTE Grand round (1)—launch
of Trust VTE policy (Local)
6. March 2010—Department of Health (DH) RA tool
(V.2) (National)
7. 21 March 2010—DH letter—Collecting of VTE RA
data to be mandatory (National)
8. 1 April 2010—electronic VTE RA (Local)
Figure 1 Overall study design,
illustrating local and national
initiatives relating to venous
thromboembolism prophylaxis.
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9. 15 April 2010—VTE reminder posters on AMU
(Local)
10. 27 April 2010—Trust RA form V.4 (in line with DH/
NICE guidance) (Local)
11. 10 May 2010—electronic VTE RA—V.2—simpliﬁed
(Local)
12. 21 May 2010—NICE guidance notes re VTE RA
data collection (National)
13. 1 June 2010—VTE data collection mandatory
(National)
14. June 2010 NICE VTE quality standard (National)
15. 6 September 2010—Trust VTE risk assessor of the
week scheme (Local)
16. 22 October 2010—VTE Grand Round (2) (Local)
17. 26 October 2010—VTE training—Pharmacists (Local)
18. 20 December 2010—VTE RA in NHS outcomes
framework 2011/12 (National)
19. 2 February 2011—How to guide for VTE RA
(National)
Local initiatives were introduced to increase staff
awareness of and facilitate the implementation of
national guidance and included both education and
provision of RA tools. A thrombosis nurse was recruited
to provide ward based training for nursing staff and edu-
cation sessions were provided for medical staff at two of
the weekly Grand rounds. Paper RA forms were initially
based on the available literature and those used by other
local hospitals. These were modiﬁed during the course
of the study in line with comments received from staff
and to comply with the revised DH RA tool introduced
in March 2010. The initial electronic RA tool introduced
in April 2010 was very cumbersome as it required a yes/
no answer to each VTE risk and each bleeding risk. This
was later simpliﬁed to electronic conﬁrmation that VTE
RA had been completed and whether or not the assess-
ment had taken place within 24 h of admission.
Ethical approval
The study was approved by the National Research Ethics
Service (Liverpool Central REC Ref 09/H1005/67),
Liverpool John Moores University Ethics Committee
(approval no 09/PBS/015); Research Governance
approval from Royal Liverpool University Hospital (study
no 3862) and was carried out in the Acute Medical Unit
(AMU) of an English university teaching hospital.
Case note review
Case notes for patients admitted during each study
period were reviewed retrospectively, following discharge
or death, to establish the frequency of VTE RA and pre-
scribing of prophylactic LMWH, evidence of VTE risk
factors and bleeding risks to assess the appropriateness
of prescribing and DVTs, PEs, deaths or episodes of
bleeding during hospitalisation.
A power calculation was performed to determine the
number of records required for detecting a difference
of 15% in the proportion of patients risk assessed
between study periods, with a power of 99%. Using a
baseline proportion of documented RAs of 5%, derived
from an earlier case note audit, 200 patient records per
study period were required. Assuming that 20% of
patients have a contraindication to treatment and using
a baseline proportion of 30% patients receiving appro-
priate prophylaxis, proportions again derived from
earlier data, 160 patients per study period would provide
96% power to detect an increase of 20% in patients
treated appropriately.
In accordance with Trust policy all patients requiring
pharmacological DVT prophylaxis should receive LMWH;
those with renal impairment (eGFR <30 ml/min) receive
a lower dose. Inappropriate prescribing of LMWH was
deﬁned as ‘prescribing for patients with at least one
known bleeding risk’ and was assessed by an expert panel
of four AMU consultant physicians. Each consultant inde-
pendently reviewed a case summary for each patient with
at least one bleeding risk who was prescribed LMWH and
indicated that LMWH was either appropriate or inappro-
priate. If there was consensus among all four consultants
the decision was accepted. Where there was initial dis-
agreement, all four consultants debated the cases until
consensus was reached.
Observations
Staff gave informed consent for observations; patients or
their carers could exclude the researcher at any time.
Patients observed were purposively selected to maximise
both the range of staff observed and variation in time
and day of admission. Staffs were aware that the study
related to the hospital admission process but not specif-
ically to VTE RA. During observations, data relating to
VTE RA and prescribing of prophylactic therapies were
recorded on a standard form with additional ﬁeld notes.
The pharmacist researcher had only social interaction
with staff, but was able to identify any inappropriate clin-
ical management with the potential to seriously
adversely impact on patient care and intervene if
required.
Interviews
Interviews with staff took place as soon as practical fol-
lowing observations, using a structured questionnaire to
ascertain their knowledge, perceived knowledge, train-
ing experiences and views on implementing VTE RA.
Data analysis
Data from the observations and interviews were coded
into themes where necessary. Descriptive analysis was
carried using SPSS V.17; statistical tests (t tests and χ2
tests treating the groups as simple categories) were
carried out using Minitab V.16. Where case notes and/
or prescription charts were missing these cases were
excluded from the relevant analyses.
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RESULTS
Case note review
The demographic details of the patients admitted
during the study are shown in table 1.
A total of 1015 patients were recruited, 930 (91.6%)
were followed up. In 54 cases the relevant admission
documentation was not available in records, leaving 876
cases suitable for analysis. The prescription chart was
missing for a further 72 cases resulting from their
exclusion from the analysis relating to prescription of
prophylaxis. Statistical analyses showed that there were
no signiﬁcant differences between the patients whose
case notes were reviewed and the remainder in terms of
gender (χ2 test; p=0.534) or length of stay (t test;
p=0.326). Observed patients were slightly older than
those not observed (t test; p=0.045) and the main causes
of admission were broadly similar (table 1).The
numbers of patients reviewed in each study period are
shown in table 2, together with details of risk factors
present.
Of the 876 patients, 719 (82.1%) had at least one VTE
risk factor and 222 (25.3%) had at least one bleeding risk
on admission. Almost a ﬁfth of all admissions (171; 19.5%)
had risk factors for both VTE and bleeding (table 2),
therefore 23.8% of the patients admitted with a VTE risk
factor also had a bleeding risk, requiring clinical judge-
ment before prescribing prophylaxis.
There was an increase in the proportion of patients
who had both VTE and bleeding risk factors during the
course of the study however this did not reach statistical
signiﬁcance (χ2 p=0.170). Over the period of the study
there was a gradual increase in the complexity of
patients treated as bed pressures resulted in more
patients with minor conditions receiving ambulatory
care which may explain this trend.
The proportion of patients with a documented com-
pleted VTE RA rose from 6.9% in study period 1 to
18.5% and 19.6% in periods 2 and 3, respectively, follow-
ing local initiatives, but to 98.7% in period 4 following
the imposition of payment-related government targets
(table 3). These changes were statistically signiﬁcant
(χ2 test; p<0.001). Three subanalyses showed that com-
parisons of periods 1 to 2 and 3 to 4 both gave p<0.001
and these were therefore statistically signiﬁcant even
when the Bonnferroni correction was applied. The com-
parison of period 2 to 3 was non-signiﬁcant (p=0.884).
Table 1 Demographic details of patients included in case
note reviews and observations
Characteristic Case note review Observations
Number 930 71
Case notes
available
876 67
Sex: male (%) 381 (43.5%) 28 (39%)
Age range (mean) 16–98 (64) years 16–98 (68)
years
Average length of
stay (mean)
1–182 (99) days 1–54 (87) days
Main causes of
admission
(descending order
of occurrence)
Infection
(285; 32.5%)
Infection
(15; 22%)
Pain (72; 8.2%) Pain (8; 12%)
Cardiac cause (60;
6.8%)
Abnormal
biochemistry*
(8; 12%)
Shortness of
breath (54; 6.2%)
Possible VTE
(7; 10%)
Abnormal
biochemistry* (51;
5.5%)
Shortness of
breath (5; 7%)
Possible VTE (46;
5.3%)
Vomiting or
diarrhoea
(5; 7%)
*Results outside of the normal range for haemoglobin, glucose,
thyroid hormones, sodium, potassium, magnesium or calcium.
Table 2 Frequency of VTE risk factors and bleeding risks
Study period November 2009 (1) January 2010 (2) April 2010 (3) April 2011 (4) Totals
Total admitted 265 255 239 256 1015
Case notes available 232/265 (87.5%) 216/255 (84.7%) 204/239 (85.4%) 224/256 (87.5%) 876/1015 (86.3%)
At least 1 VTE risk
factor*
192/232 (82.8%) 172/216 (79.6%) 161/204 (78.9%) 195/224(87.1%) 719/876 (82.1%)
95% CI (77.3% to 87.4%) (73.6% to 84.8%) (72.7% to 82.3%) (82.9% to 91.1%) (79.4 to 84.6%)
At least one bleeding
risk factor*
44/232 (19.0%) 62/216 (28.7%) 53/204 (26.0%) 63/224 (28.1%) 222/876 (25.3%)
95% CI (14.1% to 24.6%) (22.8% to 35.2%) (20.1% to 32.6%) (22.3% to 34.5%) (22.5% to 28.4%)
Risk factors for both
VTE and bleeding*
34/232 (14.7%) 44/216 (20.4%) 43/204 (21.1%) 50/224 (22.3%) 171/876 (19.5%)
95% CI (10.4% to 19.9%) (15.2% to 26.4%) (15.7% to 27.3%) (17.0% to 28.3%) (16.9% to 22.3%)
VTE risk and no
bleeding risk*
(LMWH indicated)
158/232 (68.1%) 128/216 (59.3%) 118/204 (57.8%) 145/224 (64.7%) 549/876 (62.7%)
95% CI (61.7% to 74.1%) (52.4% to 65.9%) (50.7% to 64.7%) (58.1% to 71.0%) (59.4% to 65.9%)
*No significant difference between study periods.
LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.
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Thirty-three patients had at least one bleeding risk,
but received LMWH. Independent review of all 33 case
summaries by four AMU consultants achieved consensus
agreement in 24 cases, with the remaining nine requir-
ing discussion before consensus was reached. In six cases
it was agreed that LMWH was appropriate, but was
inappropriately prescribed in the remaining 27.
Patients taking oral anticoagulants on admission are
included in those for whom LMWH was contraindicated
in table 3. Six patients were prescribed antiembolism
stockings and no patients used foot pumps during the
study. The proportion of patients appropriately pre-
scribed prophylaxis with LMWH (those with VTE risks
but no bleeding risks) rose from 49.7% in period 1 to
61.7% and 67.8% in periods 2 and 3, then to 92.6% in
period 4 (table 3). The change was statistically signiﬁcant
between periods 3 and 4 (χ2 test; p<0.001). There was
also a statistically signiﬁcant increase in the proportion of
patients who were prescribed LMWH inappropriately in
period 4 compared with the three earlier study periods
(χ2 test P=0.002). Three subanalyses of periods 1, 2 and 3
to period 4 were carried out with Bonnferroni correction.
Comparison of periods 1 to 4 and 3 to 4 were statistically
signiﬁcant (p=0.002 and 0.006, respectively). The com-
parison of period 2 to 4 was non-signiﬁcant (p=0.117).
Observations
During the four data collection periods a total of 71
patient admissions were observed, involving 35 doctors
(four consultant/specialist registrar, four specialist
trainee year 4/5, nine specialist trainee year 1/2 and 18
foundation) and one advanced nurse practitioner.
Patient details are shown in table 1.
The numbers of observations, plus numbers of RAs per-
formed and appropriate VTE prophylaxis prescribed are
shown in table 3. No RA forms were completed in period
1, and while this increased in periods 2 and 3, a greater
change was noted between periods 3 and 4. Placement of
RA forms with medication charts prior to period 2 resulted
in only seven of 21 being completed, ﬁve being actively
removed and nine being ignored. An electronic RA form
implemented prior to period 3 was not used by staff, with
only four of the 14 admissions assessed using this process.
Over the ﬁrst three study periods, only 8 of the 51 patients
(16%) observed were asked questions relating to previous
personal or family history of VTE or warfarin use, three of
Table 3 Frequency of VTE risk assessment and appropriate prescribing of LMWH
Study period November 2009 (1) January 2010 (2) April 2010 (3) April 2011 (4)
Total admitted All admissions 265 255 239 256
Case notes available 232/265 (87.5%) 216/255 (84.7%) 204/239 (85.4%) 224/256 (87.5%)
VTE risk assessment
completed*
16/232 (6.9%) 40/216 (18.5%) 40/204 (19.6%) 221/224 (98.7%)
Prescription charts and
case notes available
205/265 (77.4%) 201/255 (78.8%) 189/239 (79.1%) 209/256 (81.6%)
LMWH indicated 147/205 (71.7%) 115/201 (57.2%) 115/189 (60.8%) 135/209 (64.6%)
95% CI (65.0% to 77.8%) (50.1% to 64.3%) (53.5% to 67.8%) (57.7% to 71.1%)
LMWH prescribed
appropriately* (patient
has VTE risk factors
and no bleeding risks)
73/147 (49.7%) 71/115 (61.7%) 78/115 (67.8%) 126/136 (92.6%)
95% CI (41.3% to 58.0%) (52.2% to 70.6%) (58.5% to 76.2%) 86.9% to 96.4%)
LMWH contra
indicated
32/205 (15.6%) 49/201 (24.4%) 39/189 (20.6%) 43/209 (20.6%)
95% CI (10.9% to 21.3%) (18.6 to 30.9%) (15.1% to 27.1%) (15.3% to 26.7%)
LMWH prescribed
inappropriately**
1/32 (3%) 9/49 (18%) 3/39 (8%) 14/43 (33%)
95% CI (0% to 16%) (9% to 32%) (2% to 21%) (19% to 49%)
Number of admissions
observed
Observations 16 21 14 20
VTE risk assessment
completed
0/16 (0%) 7/21 (33%) 4/14 (29%) 15/20 (75%)
95% CI (0% to 17%) (15% to 60%) (8% to 58%) (51% to 91%)
LMWH prescribed
appropriately
9/16 (56%) 12/21 (57%) 7/14 (50%) 12/20 (60%)
95% CI (30% to 80%) (34% to 78%) (23% to 77%) (36% to 81%)
LMWH prescribed
inappropriately
0/16 (0%) 2/21 (10%) 0/14 (0%) 1/20 (5%)
95% CI (0% to 17%) (1% to 30%) (0% to 19%) (0% to 25%)
Significant differences between study periods *p<0.001; **p=0.002.
LMWH, low-molecular-weight heparin; VTE, venous thromboembolism.
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whom had presented with symptoms suggestive of VTE,
whereas in period 4, 6 of the 20 observed (30%) were
asked VTE-related questions, only one of whom presented
with symptoms suggestive of VTE.
Interviews
All 24 healthcare staff observed during periods 1, 2 and 3
were interviewed; (three consultant/specialist registrar,
two specialist trainee year 4/5, six specialist trainee year
1/2, 12 foundation and one advanced nurse practi-
tioner), of whom 13 (58%) had undergone VTE training.
There was no correlation between staff receiving training
and whether or not VTE RA was completed (χ2 test,
p=0.106). Self-rated knowledge of VTE RA was ‘good’ in
nine (38%), ‘average’ in 14 (58%) and ‘below average’ in
1 (4%). The number of spontaneously listed VTE risk
factors ranged from 3 to 8 of a possible 18 and of bleed-
ing risks, 1 to 3 of 12. There was no statistically signiﬁcant
evidence of any difference in actual knowledge between
staff with below average or average perceived knowledge
or those with good perceived knowledge (Mann-Whitney
test, p=0.2105). Staff perceptions of the proportion of
medical patients with VTE risk factors ranged from 30%
to 90%, only 13 believed that over 80% would be at risk,
while the majority (20/24; 83%) estimated that less than
20% of patients would have both VTE and bleeding risks.
Only eight staffs were aware of any national policies or
guidance on VTE RA, although the DH working group
report was published in 2007 and the ﬁrst DH VTE RA
tool was published in September 2008, none of the inter-
viewees had actually seen these documents.
The majority of staffs (22; 88%) felt that responsibility
for VTE RA should fall to the clerking doctor or nurse,
but 15 (63%) felt the actual responsibility was unclear.
Open questions elicited suggestions that the involvement
of multiple staff in individual admissions, interruptions,
lack of awareness, time pressures and the lack of user-
friendliness of the tools provided may contribute to
failure to conduct the assessment. Recommendations for
improving performance related mainly to increasing
training and raising awareness, the need for strong lead-
ership and empowerment of nurses.
DISCUSSION
During the ﬁrst three observation periods, from
November 2009 until April 2010, VTE RAs were not rou-
tinely carried out during the hospital admission process
and on occasion staff made a deliberate decision not to
complete an assessment, as shown by forms being dis-
carded. There was no evidence that staff who had
received VTE training were any more likely to carry out
RA. Despite this, the majority of the staff interviewed felt
that the admitting doctor or specialist nurse was the
most appropriate person to conduct the VTE RA due to
the complexity of data needed and the clinical interpret-
ation necessary for safe, appropriate prophylaxis.
The dramatic increase in both the number of patients
risk assessed for VTE and the number appropriately
treated with LMWH in period 4, April 2011, followed
the introduction of national mandatory data collection
in June 2010. There was an associated increase in the
number of patients who received LMWH inappropri-
ately. However, as there were a minimum of three initia-
tives between each of the data collection periods it is
difﬁcult to attribute the changes to any particular inter-
vention. The apparent impact of national mandatory
data collection may have been as a result of increased
uptake of local initiatives.
Comparison with other studies
The patients in our study differed in the most common
causes for admission from those in a large international
study;25 due to the local policy of directing patients with
acute cardiac conditions to a Heart Emergency Centre,
however we believe this was unlikely to affect staff
behaviour.
Implementing guidelines in practice is recognised as
being difﬁcult.25–27 The staff interviewed in this study
considered that the admitting doctor was the most suit-
able person to carry out the VTE RA and prescribing,
which concurs with the ﬁndings of a study conducted in
the USA.26 Various systematic reviews have examined the
difﬁculties of implementing guidelines, one concluding
that there is no ‘magic bullet’ in terms of the most
effective strategy for implementation in hospitals.27
Barriers identiﬁed to guideline implementation have
been classiﬁed into three broad categories; knowledge,
including lack of familiarity and awareness; attitudes,
including failure to believe that the intervention will
have the desired outcome and behavioural factors, such
as lack of time.28 The interviews in the present study
identiﬁed similar factors; doctors were unaware of local
and national guidance, they lacked motivation, they
were unaware of the risks of VTE and commented that
the time taken to carry out a RA was an issue. Small
group training with active participation has been found
to be effective in policy implementation in contrast to
courses alone which had mixed effects.29 In our study,
just over half of admitting staff had received training in
VTE RA, which was in lecture format whether provided
at medical school or at the hospital, which may contrib-
ute to the lack of association between training in and
carrying out RAs.
A meta-analysis of strategies to improve VTE prophy-
laxis carried out in 2005 found that passive dissemin-
ation of guidelines was generally ineffective30 which
supports our ﬁndings that the initiatives prior to June
2010 resulted in limited improvement. Other work has
demonstrated the value of opinion leaders in guideline
implementation,31 which was most likely the reason for
the signiﬁcant improvement achieved in the last study
period. Following the introduction of mandatory data
collection, government targets and associated ﬁnancial
penalties in June 2010, VTE RA became consultant-led
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as a result of pressure from Trust managers. This,
together with continuous reminders during ward
rounds, emphasised the importance of VTE RA to
junior staff and the target of at least 90% of patients
having a RA performed on admission was exceeded. In
addition, a Trust requirement for RA to be completed
by a senior doctor in the event of its omission during
initial admission resulted in almost 100% of patients
having been assessed within 24 h. An American study
published in 201232 has shown that introduction of a
mandatory computerised decision support tool had a
similar signiﬁcant beneﬁcial effect on both VTE RA and
prescription of appropriate prophylaxis.
VTE RA was one of the ﬁrst quality standards with a
ﬁnancial sanction to be issued by the DH in 2010. While
the results show that the 90% VTE RA target was
achieved in April 2011, this standard will need to be
maintained in a culture of organisational change and
additional targets. Financial targets are a relatively new
concept in secondary care in the NHS: they have been
used more widely in primary care. A recent Cochrane
review33 found that there was little evidence either for
or against their use in primary care and it has been sug-
gested that there may be unintended consequences.33 34
In addition, an analysis of CQUIN targets in London
published this year showed that only 38% of London
Trusts achieved the full payment for the VTE CQUIN in
2010/11 and that performance in a CQUIN indicator
does not always correlate with other quality indicators.35
A checklist has recently been published36 to help decide
whether a ﬁnancial incentive is appropriate in a particu-
lar clinical scenario and if so provide some guidance for
the development of a successful initiative.
CONCLUSION
This study shows that a national ﬁnancial sanction result-
ing in a consultant-led approach was associated with
effective implementation of guidance. However, it
remains to be seen whether the level of achievement
can be maintained as new targets are added in a culture
of organisational change.
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